- Home
- IPA vs LGVN Comparison
IPA vs LGVN Comparison
Compare IPA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- LGVN
- Stock Information
- Founded
- IPA 1983
- LGVN 2014
- Country
- IPA United States
- LGVN United States
- Employees
- IPA N/A
- LGVN 25
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- IPA Health Care
- LGVN Health Care
- Exchange
- IPA Nasdaq
- LGVN Nasdaq
- Market Cap
- IPA 20.6M
- LGVN 23.4M
- IPO Year
- IPA 2017
- LGVN 2021
- Fundamental
- Price
- IPA $0.45
- LGVN $1.34
- Analyst Decision
- IPA Strong Buy
- LGVN Strong Buy
- Analyst Count
- IPA 2
- LGVN 3
- Target Price
- IPA $4.00
- LGVN $8.67
- AVG Volume (30 Days)
- IPA 407.1K
- LGVN 122.2K
- Earning Date
- IPA 03-28-2025
- LGVN 05-08-2025
- Dividend Yield
- IPA N/A
- LGVN N/A
- EPS Growth
- IPA N/A
- LGVN N/A
- EPS
- IPA N/A
- LGVN N/A
- Revenue
- IPA $16,581,105.00
- LGVN $2,392,000.00
- Revenue This Year
- IPA $4.67
- LGVN $1.30
- Revenue Next Year
- IPA $14.15
- LGVN $19.15
- P/E Ratio
- IPA N/A
- LGVN N/A
- Revenue Growth
- IPA 1.34
- LGVN 237.38
- 52 Week Low
- IPA $0.27
- LGVN $0.77
- 52 Week High
- IPA $1.36
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- IPA 52.32
- LGVN 38.24
- Support Level
- IPA $0.45
- LGVN $1.48
- Resistance Level
- IPA $0.48
- LGVN $1.77
- Average True Range (ATR)
- IPA 0.03
- LGVN 0.13
- MACD
- IPA 0.00
- LGVN -0.02
- Stochastic Oscillator
- IPA 55.57
- LGVN 7.55
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.